6505--Notice of Intent - Sole Source for Pluvicto
| Agency: | VETERANS AFFAIRS, DEPARTMENT OF |
|---|---|
| State: | California |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Sep 16, 2025 |
| Due Date: | Sep 19, 2025 |
| Solicitation No: | 36C26125Q0797 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Sep 16, 2025 07:13 pm EDT
- Original Response Date: Sep 19, 2025 12:00 pm EDT
- Inactive Policy: 15 days after response date
- Original Inactive Date: Oct 04, 2025
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 325412 - Pharmaceutical Preparation Manufacturing
-
Place of Performance:
Mather , CA 95655USA
Department of Veterans Affairs (VA), Regional Procurement Office West (RPOW), Network Contracting Office (NCO) 21, on behalf of Veterans Integrated Service Network (VISN) 21 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical. Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation. This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. Interested parties may give written notice to victoria.torres@va.gov by 5:00pm PDT on 09/17/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to victoria.torres@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
- 10535 HOSPITAL WAY
- MATHER , CA 95655
- USA
- VICTORIA TORRES
- VICTORIA.TORRES@VA.GOV
- Sep 16, 2025 07:13 pm EDTSpecial Notice (Original)
See Also
Follow TympStar Pro analyzer Active Contract Opportunity Notice ID HT941026Q2088 Related Notice Department/Ind.
DEPT OF DEFENSE
Due by 9/22/2026
Solicitation Number: RFB-IS-27200169 Title: KODAK i4250 SCANNER (BRAND ONLY) Department: Internal Services Department
County of Los Angeles
Due by 9/28/2026
Bid Title: 2026/2027 Pavement Management System RFP Category: Public Works Projects (Maintenance &
City of Citrus Heights
The work includes the procurement and delivery of six bulkheads to isolate three
San Diego County Water Authority
Due by 9/24/2026